{"filing":{"accession_number":"0001809519-26-000153","cik":"0001809519","ticker":"GDRX","company_name":"GoodRx Holdings, Inc.","form":"8-K","filing_date":"2026-08-05","report_date":"2026-07-31","primary_document":"gdrx-20260731.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1809519/000180951926000153/gdrx-20260731.htm"},"events":[{"id":25261,"run_id":22922,"accession_number":"0001809519-26-000153","anchor_item_number":"5.02","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"summary":"The filing discloses both the departure of CFO Christopher McGinnis (effective August 5, 2026) and the appointment of Justin Fengler as Chief Financial Officer \u0026 Treasurer (effective August 6, 2026). While both events occur, the principal disclosed action centers on Fengler's appointment to the CFO role, which includes material compensatory arrangements ($600K RSU, $600K PSU, and $100K cash payment). The appointment of a new CFO is material to investors assessing financial leadership continuity and governance.","company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","filing_date":"2026-08-05","form":"8-K","submitted_at":null,"items":[{"id":26039,"accession_number":"0001809519-26-000153","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the departure of CFO Christopher McGinnis (effective August 5, 2026) and the appointment of Justin Fengler as Chief Financial Officer \u0026 Treasurer (effective August 6, 2026). While both events occur, the principal disclosed action centers on Fengler's appointment to the CFO role, which includes material compensatory arrangements ($600K RSU, $600K PSU, and $100K cash payment). The appointment of a new CFO is material to investors assessing financial leadership continuity and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:23:44.319397+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26039,"accession_number":"0001809519-26-000153","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers;","event_type":"exec_appointment","event_domain":"governance","is_material":true,"confidence":0.75,"reasoning":"The filing discloses both the departure of CFO Christopher McGinnis (effective August 5, 2026) and the appointment of Justin Fengler as Chief Financial Officer \u0026 Treasurer (effective August 6, 2026). While both events occur, the principal disclosed action centers on Fengler's appointment to the CFO role, which includes material compensatory arrangements ($600K RSU, $600K PSU, and $100K cash payment). The appointment of a new CFO is material to investors assessing financial leadership continuity and governance.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-08T02:23:44.319397+00:00","company_name":"GoodRx Holdings, Inc.","ticker":"GDRX","filing_date":"2026-08-05"}]}